PT - JOURNAL ARTICLE AU - Andrew R. Crowley AU - Harini Natarajan AU - Andrew P. Hederman AU - Carly A. Bobak AU - Joshua A. Weiner AU - Wendy Wieland-Alter AU - Jiwon Lee AU - Evan M. Bloch AU - Aaron A.R. Tobian AU - Andrew D. Redd AU - Joel N. Blankson AU - Dana Wolf AU - Tessa Goetghebuer AU - Arnaud Marchant AU - Ruth I. Connor AU - Peter F. Wright AU - Margaret E. Ackerman TI - Boosting of Cross-Reactive Antibodies to Endemic Coronaviruses by SARS-CoV-2 Infection but not Vaccination with Stabilized Spike AID - 10.1101/2021.10.27.21265574 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.27.21265574 4099 - http://medrxiv.org/content/early/2021/10/28/2021.10.27.21265574.short 4100 - http://medrxiv.org/content/early/2021/10/28/2021.10.27.21265574.full AB - Pre-existing antibodies to endemic coronaviruses (CoV) that cross-react with SARS-CoV-2 have the potential to influence the antibody response to COVID-19 vaccination and infection for better or worse. In this observational study of mucosal and systemic humoral immunity in acutely infected, convalescent, and vaccinated subjects, we tested for cross reactivity against endemic CoV spike (S) protein at subdomain resolution. Elevated responses, particularly to the β-CoV OC43, were observed in all natural infection cohorts tested and were correlated with the response to SARS-CoV-2. The kinetics of this response and isotypes involved suggest that infection boosts preexisting antibody lineages raised against prior endemic CoV exposure that cross react. While further research is needed to discern whether this recalled response is desirable or detrimental, the boosted antibodies principally targeted the better conserved S2 subdomain of the viral spike and were not associated with neutralization activity. In contrast, vaccination with a stabilized spike mRNA vaccine did not robustly boost cross-reactive antibodies, suggesting differing antigenicity and immunogenicity. In sum, this study provides evidence that antibodies targeting endemic CoV are robustly boosted in response to SARS-CoV-2 infection but not to vaccination with stabilized S, and that depending on conformation or other factors, the S2 subdomain of the spike protein triggers a rapidly recalled, IgG-dominated response that lacks neutralization activity.Graphical Abstract Antibody responses to SARS-CoV-2 and endemic CoV spike proteins were measured in diverse cohorts. While antibodies to SARS-CoV-2 were induced across all isotypes, only IgA and IgG responses to endemic CoV were robustly boosted, and only among naturally-infected but not vaccinated individuals. These recalled, cross-reactive responses to endemic CoV primarily recognized the better conserved S2 domain and were non-neutralizing. While other antiviral activities of broadly cross-reactive S2-specifc antibodies are not known, the differing antigenicity of natural infection and vaccination with stabilized pre-fusion spike has potential implications for the breadth and level of protection afforded by each.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, as well as extramural support from the National Institute of Allergy and Infectious Diseases (U19AI145825 to M.E.A, R01AI120938, R01AI120938S1, and R01AI128779 to A.A.R.T.), National Heart Lung and Blood Institute (K23HL151826 to E.M.B.), National Institute of General Medical Sciences (P20-GM113132 BioMT Molecular Tools Core).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subject research was approved by the Johns Hopkins University School of Medicine Institutional Review Board and the Dartmouth-Hitchcock Medical Center and CHU St. Pierre and Hadassah Medical Center and BioIVT clinical site Committees for the Protection of Human SubjectsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.